Treatment of Vitiligo with the Topical Janus Kinase Inhibitor Ruxolitinib: A 32-Week Open-Label Extension Study with Optional Narrow-Band Ultraviolet B

    February 2018 in “ Journal of the American Academy of Dermatology ”
    Deep Joshipura, Abdulaziz Alomran, Pedro Zancanaro, David Rosmarin
    Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

    We don't know much about this study yet.

    Read the full study on jaad.org →
    Discuss this study in the Community →

    Research cited in this study 1

    1. Rapid Skin Repigmentation on Oral Ruxolitinib in a Patient with Coexistent Vitiligo and Alopecia Areata Journal of the American Academy of Dermatology · 2015

    Related research 4

    1. Treatment With Oral Janus Kinase Inhibitors in Adult Patients With Alopecia Areata: A Systematic Review and Meta-Analysis Journal of the American Academy of Dermatology · 2023
    2. Ruxolitinib for the Treatment of Severe Alopecia Areata Journal of the American Academy of Dermatology · 2018
    3. Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata Drug design, development and therapy · 2018
    4. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016